Enrofloxacin

Product Overview

Enrofloxacin is the first fluoroquinolone antibiotic developed specifically for veterinary use. Discovered and developed by Bayer AG, it has become one of the most widely prescribed veterinary antibiotics globally. Enrofloxacin exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes critical for bacterial DNA replication, transcription, and repair.

Enrofloxacin demonstrates concentration-dependent bactericidal activity against a broad spectrum of clinically relevant pathogens including Gram-negative bacteria (E. coli, Salmonella spp., Pasteurella spp., Actinobacillus pleuropneumoniae, Pseudomonas aeruginosa), Gram-positive bacteria (Staphylococcus spp., Streptococcus spp.), and Mycoplasma species. In the body, enrofloxacin is partially metabolized to ciprofloxacin, an equally active fluoroquinolone, which contributes to its overall therapeutic efficacy. Its excellent bioavailability, extensive tissue distribution, and high intracellular concentrations make it particularly valuable for treating respiratory, enteric, and systemic infections.

Quality Specifications

Purity	As per EP/CPV monograph
Residual Solvents	Compliant with ICH Q3C
Heavy Metals	Compliant with pharmacopoeia limits
GMP Status	Manufactured under GMP conditions

Veterinary Applications

Therapeutic Areas

• Poultry: Respiratory and enteric infections, mycoplasmosis
• Swine: Bacterial enteritis, respiratory disease complex
• Cattle: Bovine respiratory disease (BRD)
• Companion Animals: Skin, urinary tract, and respiratory infections